Biotech financings and M&A
activeReport on major biotech private financings / IPOs and M&A.
3 candidate storiesdeep depthlast week
Reporters
2
2 active
Target runtime
18m
Oncology therapeutics VC daily
Generation mode
Live
Live APIs configured
Editor Snapshot
Oncology therapeutics VC daily
Audience: an oncology-focused biotech venture capitalist with technical depth. Commentary should assume an appropriate level of context.
Conversational, precise, and audio-first. Make the briefing feel like a thoughtful private intelligence memo spoken aloud.
Allocations: Spend roughly equal time across active reporters unless one topic has materially stronger stories.
Priorities: Prioritize genuinely new developments, primary sources when possible, and clear explanations of why each story matters (but with the context of the target audience - don't make ov…
Reporters
New ReporterPreclinical research
activeCovers early-stage research published by PIs at academic institutions, biotech, pharma.
3 candidate storiesdeep depthlast month
Recent Episodes
All EpisodesRecent Breakthroughs in Oncology Financing and Research
Created May 18, 2026, 2:49 AM
Completed May 18, 2026, 3:58 AM
Latest Developments in Oncology and Biotech Financing
Created May 17, 2026, 3:31 AM
Completed May 17, 2026, 4:22 AM
Latest Trends in Oncology Biotech Funding and Research
Created May 14, 2026, 3:07 PM
Completed May 14, 2026, 4:46 PM
Insights on Emerging Trends in Oncology and Biotech Finance
Created May 14, 2026, 1:03 AM
Completed May 14, 2026, 4:18 AM
Coverage memory
Recently approved topics
This running log is fed back into future generations so the editor can avoid stale repetition and each reporter can remember which approved subtopics they have already covered.
Biotech financings and M&A
mediumrepeat after 2 monthsReporter: Biotech financings and M&A
Last covered May 18, 2026, 2:49 AM
The partnership between BMS and Hengrui Pharma showcases a broader trend of collaboration boosting oncology drug development efforts, meriting ongoing observation.
Preclinical research
narrowrepeat after 2 monthsReporter: Preclinical research
Last covered May 18, 2026, 2:49 AM
Insights into mitochondrial dynamics offer novel therapeutic avenues but should not be repeated frequently due to specificity.
Preclinical research
narrowrepeat after 2 monthsReporter: Biotech financings and M&A
Last covered May 17, 2026, 4:22 AM
Discusses the promising combination of INBRX-106 with Keytruda, highlighting evolving treatment landscapes that need monitoring without frequent repeats.